Answers are grounded in this paper and cite their sources.
HER2-low represents ∼65% of HR+/HER2-negative(-) BC; there is conflicting evidence regarding the potential association with higher pathologic complete response (pCR) and differential prognosis compared to HR+/HER2 0. Moreover, molecular changes induced by NAT have not been studied so far.
No takes yet. Share an insight, caveat, or question.
Schettini et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: